Ahmed Kashif, Vohra Hunaid A, Milne Alison, Langley Stephen M
Department of Cardiothoracic Surgery, Southampton University Hospitals NHS Trust, Southampton, UK.
J Cardiothorac Surg. 2008 Jan 30;3:5. doi: 10.1186/1749-8090-3-5.
Essential Thrombocythcythaemia (ET) is an uncommon type of myeloproliferative disorder, characterised by both thrombotic and haemorrhagic diathesis. No clear guidelines exist for the pre- and post-operative management of patients undergoing cardiac surgery in the haematological and surgical literature. This condition has profound implications in patients undergoing cardiac surgery with the use of cardiopulmonary bypass, where heparin is used for anti-coagulation. This dilemma is further compounded in the setting of a young patient undergoing aortic valve replacement (AVR), where insertion of a mechanical prosthesis would be the procedure of choice. This would require life-long anticoagulation with warfarin which can predispose these patients to catastrophic bleeding. Using a tissue valve will subject the patient to multiple redo operations in the patient's lifetime. We report a young patient with ET requiring AVR and discuss the dilemmas surrounding the choice of prosthesis in this patient.
原发性血小板增多症(ET)是一种罕见的骨髓增殖性疾病,其特征为既有血栓形成倾向又有出血素质。在血液学和外科文献中,对于接受心脏手术患者的术前和术后管理尚无明确的指导方针。这种情况对于接受体外循环心脏手术的患者具有深远影响,因为在这类手术中会使用肝素进行抗凝。在一名接受主动脉瓣置换术(AVR)的年轻患者中,这种困境更加复杂,因为植入机械瓣膜将是首选手术方式。这将需要使用华法林进行终身抗凝,而这可能使这些患者面临灾难性出血的风险。使用组织瓣膜则会使患者在其一生中需要多次再次手术。我们报告了一名患有ET且需要进行AVR的年轻患者,并讨论了围绕该患者假体选择的困境。